Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies

  • Artigas, Francesc
  • Bortolozzi, Analía
  • Celada, Pau
Major depressive disorder (MDD) is a severe psychiatric syndrome with high prevalence and socioeconomic impact. Current antidepressant treatments are based on the blockade of serotonin (5-hydroxytryptamine, 5-HT) and/or noradrenaline transporters. These drugs show slow onset of clinical action and limited efficacy, partly due to the activation of physiological negative feed-back mechanisms operating through autoreceptors (5-HT1A, 5-HT1B, α2-adrenoceptors) and postsynaptic receptors (e.g., 5-HT3). As a result, clinically-relevant doses of reuptake inhibitors increase extracellular (active) 5-HT concentrations in the midbrain raphe nuclei but not in forebrain, as indicated by rodent microdialysis studies and by PET-scan studies in primate/human brain. The prevention of these self-inhibitory mechanisms by antagonists of the above receptors augments preclinical and clinical antidepressant effects. Hence, the mixed ß-adrenoceptor/5-HT1A antagonist pindolol accelerated, and in some cases enhanced, the clinical action of selective serotonin reuptake inhibitors (SSRI). This strategy has been incorporated into two new multi-target antidepressant drugs, vilazodone and vortioxetine, which combine 5-HT reuptake inhibition and partial agonism at 5-HT1A receptors. Vortioxetine shows also high affinity for other 5-HT receptors, including excitatory 5-HT3 receptors located in cortical and hippocampal GABA interneurons. 5-HT3 receptor blockade by vortioxetine enhances pyramidal neuron activity in prefrontal cortex as well as cortical and hippocampal 5-HT release. It is still too soon to know whether these new antidepressants will represent a real advance over existing drugs in the real world. However, their development opened the way to future antidepressant drugs based on the prevention of local and distal self-inhibitory mechanisms attenuating monoamine activity., Support from the following grants is acknowledged: grants SAF2015-68346-P, SAF2016-75797-R and Retos-Colaboración Subprogram RTC-2014-2812-1, Ministry of Economy, Industry and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; grants PI12/00156, PI13/01390 and PI16/00287, Instituto de Salud Carlos III, co-financed by European Regional Development Fund (ERDF), UE, “A way to build Europe”; the Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya (Grup de Recerca Consolidat 2014SGR798)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for parkinson’s disease

  • Alarcón-Arís, Diana
  • Recasens, Ariadna
  • Galofré, Mireia
  • Carballo-Carbajal, Iria
  • Zacchi, Nicolás
  • Ruiz-Bronchal, Esther
  • Pavia-Collado, Rubén
  • Chica, M. Rosario
  • Ferrés-Coy, Albert
  • Santos, Marina
  • Revilla, Raquel
  • Montefeltro, Andrés
  • Fariñas, Isabel
  • Artigas, Francesc
  • Vila, Miquel
  • Bortolozzi, Analía
Progressive neuronal death in brainstem nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson’s disease (PD). Reduction of α-synuclein levels is therefore a potential therapy for PD. However, because α-synuclein is essential for neuronal development and function, α-synuclein elimination would dramatically impact brain function. We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration. Here, we used this strategy to conjugate inhibitory oligonucleotides, siRNA and antisense oligonucleotide (ASO), with the triple monoamine reuptake inhibitor indatraline (IND), to selectively reduce α-synuclein expression in the brainstem monoamine nuclei of mice after intranasal delivery. Following internalization of the conjugated oligonucleotides in monoamine neurons, reduced levels of endogenous α-synuclein mRNA and protein were found in substantia nigra pars compacta (SNc), ventral tegmental area (VTA), dorsal raphe nucleus (DR), and locus coeruleus (LC). α-Synuclein knockdown by ∼20%–40% did not cause monoaminergic neurodegeneration and enhanced forebrain dopamine (DA) and 5-HT release. Conversely, a modest human α-synuclein overexpression in DA neurons markedly reduced striatal DA release. These results indicate that α-synuclein negatively regulates monoamine neurotransmission and set the stage for the testing of non-viral inhibitory oligonucleotides as disease-modifying agents in α-synuclein models of PD., This work was supported by grant SAF2016-75797-R (to A.B.), INNPACTO Subprogram IPT-2012- 1208-300000 (to A.B.), and Retos-Colaboración Subprogram RTC-2014-2812-1 (to M.V. and A.B.); Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; grants PI13/01897 (to M.V.) and PI13/01390 (to A.B.), Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (Spain), co-financed by ERDF; and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED). CERCA Programme/Generalitat de Catalunya is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Antisense oligonucleotide reduction of human alpha-synuclein accumulation in dopamine and serotonin neurons prevents early dysfunctions in a mouse model of Parkinson's disease

  • Alarcón-Arís, Diana
  • Ruiz-Bronchal, Esther
  • Montefeltro, Andrés
  • Artigas, Francesc
  • Bortolozzi, Analía
Trabajo presentado en el Alpha-synuclein & Parkinson’s disease Conference: Lessons from the past 20 years, celebrado en la Universitat de Barcelona los días 11 y 12 de mayo de 2017, Pathological changes in end-state of Parkinson’s disease (PD) are well characterized. However, there is an urgent need to identify early functional changes to develop new therapeutic strategies stopping the development of the illness. α-Synuclein is a protein accumulating in the brain of PD patients. We generated a mouse model overexpressing wild-type human-α-synuclein in dopamine-DA or serotonin-5-HT neurons of substantia nigra-(SNc) and raphe nuclei-(RN), respectively. These mice showed increased human-α-synuclein mRNA levels in the ipsilateral SNc and RN, without loss tyrosine hydroxylase-(TH)-positive or tryptophan hydroxylase- (TPH2)-positive neurons. Moreover, reduced DA and 5-HT release with development of αsynuclein-positive axonal swelling in striatum were found in these mice. In addition, AAV5 mice exhibited motor deficits at 8 weeks post-infection into SNc and depressive-like behaviors at 4 weeks post-infection into RN. Here, we evaluated whether reducing human-α-synuclein expression in the mesencephalic nuclei prevented early dysfunctions in the AAV5 model. We used a conjugated antisense oligonucleotide targeting intracellular human-α-synuclein (ASO1337) selectively in DA and 5-HT neurons. Mice overexpressing human-α-synuclein in the SNc/VTA or RN were treated intracerebroventricularly with vehicle, nonsense ASO sequence (ASO1227) or ASO1337 (30 or 100μg/day) during 28 days using osmotic minipumps implanted subcutaneously. ASO1337 reduced dose-dependent the human-α-synuclein mRNA levels (ASO1337 30μg/day: 60,21%±15.93; ASO1337 100μ/day: 46.71%±8.63, respect vehicle) whereas endogenous α-synuclein expression remained unaltered. Immunohistochemistry shows the reduction of human-α-synuclein protein density (vehicle: 245,56%±5.32: ASO1337 30μg/day: 177.7%±7.65; ASO1337 100μ/day: 173%±2.93, respect contralateral side). Furthermore, recovery of striatal DA release was achieved by reduction of human-α-synuclein expression in SNc/VTA. Our study indicated that the reduction of intracellular α-synuclein accumulation selectively in DA and 5-HT neurons using ASO molecules represents an optimal PD therapy., Spanish Ministry of Economy and Competitiveness, INNPACTO Subprogram IPT2012-1208-300000 and Retos-Colaboración Subprogram RTC-2014-2812-1; Instituto de Salud Carlos III PI13/01390 co-financed by the European Regional Development Fund “A way to build Europe”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Short -and long- term memory impairment in mice overexpressing alpha -and gamma- synuclein in the dopamine neurons. Implication in Parkinson' disease

  • Pavia-Collado, Rubén
  • Alarcón-Arís, Diana
  • Ruiz-Bronchal, Esther
  • Artigas, Francesc
  • Bortolozzi, Analía
Trabajo presentado en el Neuroscience 2017, celebrado en Washington del 11 al 15 de noviembre de 2017, Idiopathic Parkinson’s disease (PD) is characterized by progressive brain pathology affecting multiple neurotransmitter systems, leading to a diverse profile of autonomic, motor, cognitive and psychiatric dysfunctions. Multiple convergent lines of evidence implicate the aggregation and accumulation of α-synuclein in the PD pathogenesis. Moreover, post-translational changes of γ-synuclein increase the α-synuclein aggregation. α- and γ-Synuclein are members of the synuclein family of small cytoplasmatic neuron-specific proteins, and have been suggested to modulate the function of monoamine transporters (DAT, SERT). We previously reported that α-synuclein knockdown mice showed increased extracellular DA and 5-HT levels- compard to control mice- in caudate-putamen (CPu) and medial prefrontal cortex (mPFC) after DAT or SERT blockade with nomifensine or citalopram, respectively (Alarcón-Arís et al., in review). Given the role of monoamine neurotransmission in cognitive processes, in the present study we assessed the effects of over-expressing α- and γ-synuclein in DA neurons on short- and long-term spatial memory. We generated a mouse model overexpressing the human wild-type α- or γ-synuclein in DA neurons from the substantia nigra compacta (SNc) and ventral tegmental area (VTA) using an adeno-associated virus type-5 (AAV5)-α-synuclein or AAV10-γ-synuclein, unilaterally injected in SNc/VTA. AAV5-α-synuclein mice showed increased human α-synuclein mRNA levels in the ipsilateral SN over time, reaching a 278% of sham mice at 8 weeks post-infection. Similarly, AAV10-γ-synuclein mice reached to a maximal of 250% of sham mice. Overexpression of α- or γ-synuclein led to lower extracellular DA levels in CPu and mPFC compared to sham mice after local veratridine (50μM) or nomifensine (1-10-50μM) administration at 4-week post-infection. Moreover, overexpression of α- or γ-synuclein led to the impairment of working memory in mice, as revealed by passive avoidance and novel object recognition tests at 4-8 weeks post-infusion. Likewise, these mice showed deficits in the spatial learning using the Morris water maze. These non-motor symptoms appeared earlier than motor deficits assessed by the cylinder test and rotarod. Overall, these findings indicate that that 1) α- and γ-synuclein are directly involved in the regulation of cognitive functions, likely through changes in monoamine function, and 2) overexpression of α- or γ-synuclein in DA neurons mimics the temporal progression of clinical symptoms in PD, with early cognitive deficits appearing before motor symptoms., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective Knockdown of TASK3 Potassium Channel in Monoamine Neurons: a New Therapeutic Approach for Depression

  • Fullana, Neus
  • Ferrés-Coy, Albert
  • Ortega, Jorge E.
  • Ruiz-Bronchal, Esther
  • Paz, Verónica
  • Meana, J. Javier
  • Artigas, Francesc
  • Bortolozzi, Analía
Current pharmacological treatments for major depressive disorder (MDD) are severely compromised by both slow action and limited efficacy. RNAi strategies have been used to evoke antidepressant-like effects faster than classical drugs. Using small interfering RNA (siRNA), we herein show that TASK3 potassium channel knockdown in monoamine neurons induces antidepressant-like responses in mice. TASK3-siRNAs were conjugated to cell-specific ligands, sertraline (Ser) or reboxetine (Reb), to promote their selective accumulation in serotonin (5-HT) and norepinephrine (NE) neurons, respectively, after intranasal delivery. Following neuronal internalization of conjugated TASK3-siRNAs, reduced TASK3 mRNA and protein levels were found in the brainstem 5-HT and NE cell groups. Moreover, Ser-TASK3-siRNA induced robust antidepressant-like behaviors, enhanced the hippocampal plasticity, and potentiated the fluoxetine-induced increase on extracellular 5-HT. Similar responses, yet of lower magnitude, were detected for Reb-TASK3-siRNA. These findings provide substantial support for TASK3 as a potential target, and RNAi-based strategies as a novel therapeutic approach to treat MDD., This work was supported by the following grants: SAF2015-68346-P (F.A.); SAF2013-48586-R (J.M.); SAF2016-75797-R (A.B.); Retos-Colaboración Subprograms RTC-2014-2812-1 and RTC-2015-3309-1 (A.B.); Ministry of Economy and Competitiveness (MINECO)—European Regional Development Fund (ERDF), UE; PI13/01390, Instituto de Salud Carlos III co-financed by ERDF (A.B.); IT616-13 Basque Government—ERDF (J.M.); 20003 NARSAD Independent Investigator (A.B.); and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). CERCA Programme/Generalitat de Catalunya is also acknowledged. M.N.F. and A.F-C. are recipients of a fellowship from the Spanish Ministry of Education, Culture and Sport., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis

  • Carballo-Carbajal, Iria
  • Laguna, Ariadna
  • Romero-Giménez, Jordi
  • Cuadros, Thais
  • Bové, Jordi
  • Martinez-Vicente, Marta
  • Parent, Annabelle
  • González-Sepúlveda, Marta
  • Peñuelas, Nuria
  • Torra, Albert
  • Rodríguez-Galván, Beatriz
  • Ballabio, Andrea
  • Hasegawa, Takafumi
  • Bortolozzi, Analía
  • Gelpi, Ellen
  • Vila, Miquel
In Parkinson’s disease (PD) there is a selective degeneration of neuromelanin-containing neurons, especially substantia nigra dopaminergic neurons. In humans, neuromelanin accumulates with age, the latter being the main risk factor for PD. The contribution of neuromelanin to PD pathogenesis remains unknown because, unlike humans, common laboratory animals lack neuromelanin. Synthesis of peripheral melanins is mediated by tyrosinase, an enzyme also present at low levels in the brain. Here we report that overexpression of human tyrosinase in rat substantia nigra results in age-dependent production of human-like neuromelanin within nigral dopaminergic neurons, up to levels reached in elderly humans. In these animals, intracellular neuromelanin accumulation above a specific threshold is associated to an age-dependent PD phenotype, including hypokinesia, Lewy body-like formation and nigrostriatal neurodegeneration. Enhancing lysosomal proteostasis reduces intracellular neuromelanin and prevents neurodegeneration in tyrosinase-overexpressing animals. Our results suggest that intracellular neuromelanin levels may set the threshold for the initiation of PD., This work was supported by funds from the Fondo de Investigación Sanitaria-Instituto de Salud Carlos III (FIS-ISCIII, Spain)-European Regional Development Fund (FEDER, E.U.) (PI13/01897, to M.V.), Parkinson’s U.K. (to M.V.), Ministry of Economy and Competitiveness (MINECO, Spain) (SAF2016-77541-R and RTC-2014-2812-1, to M.V.), The Michael J. Fox Foundation (U.S.A) (ID15291, to M.V.), La Caixa Banking Foundation (Health Research Project HR17-00513, to M.V.) and CIBERNED (to M.V.). In addition, the Authors would like to acknowledge additional support from the Fundación Tatiana Pérez de Guzmán el Bueno (Spain, to A.L.), Michael J. Fox Foundation (U.S.A.) (ID11580, to A.L.), MINECO (SAF2016-75797-R, to A.Bo.) and FIS-ISCIII-FEDER (PI15/01937 to J.B. and PI13/01390 to A.Bo.). A.L. was the recipient of a post-doctoral fellowship Beatriu de Pinós (2013 BP-DGR B 00043) from the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Spain) with co-funding from the Marie Curie COFUND program (E.U.) and a postdoctoral contract SAF2015-73997-JIN from MINECO (Spain) with co-funding from FEDER (E.U.). N.P. is the recipient of a predoctoral fellowship FPI (BES-2017-080191) from MINECO (Spain). A.T. is the recipient of a pre-doctoral fellowship PFIS (FI14/00613) from the FIS-ISCIII (Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys

  • Alarcón-Arís, Diana
  • Pavia-Collado, Rubén
  • Miquel-Rio, Lluís
  • Coppola-Segovia, Valentín
  • Ferrés-Coy, Albert
  • Ruiz-Bronchal, Esther
  • Galofré, Mireia
  • Paz, Verónica
  • Campa, Leticia
  • Revilla, Raquel
  • Montefeltro, Andrés
  • Kordower, Jeffrey H.
  • Vila, M.
  • Artigas, Francesc
  • Bortolozzi, Analía
Background: Progressive neuronal death in monoaminergic nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson's disease (PD). Given that α-synuclein may be an early mediator of the pathological cascade that ultimately leads to neurodegeneration, decreased α-synuclein synthesis will abate neurotoxicity if delivered to the key affected neurons. Methods: We used a non-viral gene therapy based on a new indatraline-conjugated antisense oligonucleotide (IND-ASO) to disrupt the α-synuclein mRNA transcription selectively in monoamine neurons of a PD-like mouse model and elderly nonhuman primates. Molecular, cell biology, histological, neurochemical and behavioral assays were performed. Findings: Intracerebroventricular and intranasal IND-ASO administration for four weeks in a mouse model with AAV-mediated wild-type human α-synuclein overexpression in dopamine neurons prevented the synthesis and accumulation of α-synuclein in the connected brain regions, improving dopamine neurotransmission. Likewise, the four-week IND-ASO treatment led to decreased levels of endogenous α-synuclein protein in the midbrain monoamine nuclei of nonhuman primates, which are affected early in PD. Conclusions: : The inhibition of α-synuclein production in dopamine neurons and its accumulation in cortical/striatal projection areas may alleviate the early deficits of dopamine function, showing the high translational value of antisense oligonucleotides as a disease modifying therapy for PD and related synucleinopathies., Grants SAF2016-75797-R, RTC-2014-2812-1 and RTC-2015-3309-1, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; Grant ID 9238, Michael J. Fox Foundation; and Centres for Networked Biomedical Research on Mental Health (CIBERSAM), and on Neurodegenerative Diseases (CIBERNED).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Proteína alfa-sinucleína y modulación de los sistemas monoaminérgicos. Desde la función fisiológica a diana terapéutica utilizando ácidos nucleicos de interferencia

  • Alarcón-Arís, Diana
Tesis doctoral presentada para lograr el título de Doctor por la Universidad de Barcelona, Programa de Doctorado en Biomedicina.--Calificación: Sobresaliente cum laude, La proteína o-Slnucleína (o-Syn) se expresa de forma abundante en el cerebro, representado aproximadamente el 1% del total de la proteína citosólica, localizada principalmente en las terminales slnápticas. Sin embargo, su rol fisiológico todavía es desconocido. Además, múltiples estudios han demostrado que la acumulación de o­Syn tiene un papel crucial en la neuropatologfa de la enfermedad de Parkinson (PO). Los mecanismos exactos por los cuales o-Syn causa las alteraciones histológicas, que conducen principalmente en la muerte de neuronas mesencefállcas dopaminérgicas (DA), alteraciones en el circuito de los ganglios basales y presencia de síntomas motores y no motores aún no están claros. Se ha sugerido que la toxicidad asociada a o-Syn está mediada por varias formas reactivas de la proteína que afectan a distintos procesos celulares. En la presente Tesis decidimos examinar en primer lugar el rol fisiológico de o-Syn sobre la actividad de los componentes que mantienen la homeostasis de la neurotransmisión monoamlnérgica y, de los procesos de plasticidad y neurogénesis dependientes de inervación DA. En segundo lugar, nos propusimos evaluar la efectividad de RNAs terapéuticos incluyendo RNAs pequeños de interferencia (siRNAs) y oligonucleótidos antisentldo (AS0s) conjugados con indatralina (IND, triple inhlbldor de los transportadres de monoaminas) en modelos murlons de PO y en monos. Concretamente, abordamos la 1) examinaclón de las consecuencias funcionales sobre la neurotransmisión monoaminérglca asociadas a distintos niveles de expresion intracelular de a-Syn en neuronas DA y serotonlnérglcas (5-HT) usando modelos murlnos transgénlcos de sobre-expresión y knockdown Inducidos por secuencias de siRNAs o ASOs; 2) examinación del rol sináptico de o-Syn en los aferentes DA de la sustancia nlgra pars compacta (SNc) sobre los procesos de mantenimiento, auto-renovación y diferenciación de las células neuronales progenitoras, usando modelos murinos nulos para o-Syn o de sobre-expresión inducidos por vectores adenoasoclados (AAV); 3) generación y caracterización de modelos murinos de PD basado en la sobre-expresión de la forma wild-type humana de o-Syn inducido por AAVS en las neuronas DA de la SNc/área tegmental ventral {VfA) o en las neuronas 5-HT de los núcleos del rafe. Examlnación de la eficacia y selectividad de una secuencia específica de ASO conjugada con IND para disminuir la producción de o-Syn en el modelo de sobre-expresión enlas neuronas DA y 5-HT y reversión del fenotipo conductual; y 4) evaluación de la eficacia y selectividad de la secuencia de ASO conjugada con IND para reducir la síntesis de a-Syn en los núcleos monoaminérgicos de monos Rhesus envejecidos. En la presente Tesis demostramos que la proteína a-Syn actúa como regulador sináptico negativo de la neurotransmisión DA y 5-HT en áreas corticales y subcorticales y es un requerimiento esencial para mantener el potencial neurogénico adulto. Además, la conjugación de una secuencia siRNA o ASO especifica contra a-Sin con IND favorece la acumulación in vivo del ollgonucleótido selectivamente en las neuronas monoaminérgicas (DA, NA y 5-HT). La sobre-expresión de la forma humana WT de a-Sin en la SNc/VfA o en los núcleos del rafe de ratón utilizando un vector AAVS recapitula algunos de los síntomas cardinales de la PO. La terapia con ASO conjugado reduce los niveles de a-Syn en los modelos de sinucleinopatía en las neuronas DA de la SNc/VTA y 5-HT en los núcleos del rafe asl como en los monos Rhesus, sugiriendo que los RNA terapéuticos no virales pueden convertirse en una estrategia potencial en el tratamiento de la PD., El presente trabajo ha sido financiado por los siguientes proyectos: 1. “Supresión de la expresión de α-sinucleína y de la actividad de PDE10 como estrategia terapéutica combinada para el tratamiento de Parkinson y mejora de las disfunciones cognitivas” con código IPT-2012-1208-300000 y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). 2. “Sinucleínas, depresión y enfermedad de Parkinson. Nuevas estrategias terapéuticas basadas en ácidos nucleicos de interferencia” con código PI13/01390 y financiado por el Fondo de Investigación Sanitaria-Instituto de Salud Carlos III y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). 3. “Nuevas estrategias terapéuticas para el tratamiento de sinucleinopatías” con código RTC-2014-2812-1 y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado el Fondo Europeo de Desarrollo Regional (FEDER). 4. “Pharmacokinetic and pharmacodynamic characterization of a novel therapy to silence selectively alpha-synuclein in monoaminergic neurons of rat" con código 9238 y financiado por La Fundación Michael J. Fox. 5. “Desarrollo de una terapia para el tratamiento de variantes genéticas de αsinucleína en la enfermedad de Parkinson” con código RTC-2015-3309-1 y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER). 6. “Sinucleinopatías y oligonucleótidos inhibitorios: Rol de α- y γ-sinucleínas en la regulación de la función cognitiva” con código SAF2016-75797-R y financiado por el Ministerio de Economía y Competitividad (MINECO) y cofinanciado el Fondo Europeo de Desarrollo Regional (FEDER).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients

  • Recasens, Ariadna
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Parent, Annabelle|||0000-0002-6195-812X
  • Bové, Jordi|||0000-0002-2529-205X
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Tolosa, Eduardo
  • Vila Bover, Miquel|||0000-0002-1352-989X
The online version of this article (10.1186/s40478-018-0509-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mitochondrial Quality Control in Neurodegenerative Diseases, Focus on Parkinson's Disease and Huntington's Disease

  • Franco Iborra, Sandra|||0000-0001-7385-657X
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Perier, Celine|||0000-0001-7446-8173
In recent years, several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease (PD) and Huntington's disease (HD). Despite distinct clinical and pathological features, these two neurodegenerative diseases share critical processes, such as the presence of misfolded and/or aggregated proteins, oxidative stress, and mitochondrial anomalies. Even though the mitochondria are commonly regarded as the "powerhouses" of the cell, they are involved in a multitude of cellular events such as heme metabolism, calcium homeostasis, and apoptosis. Disruption of mitochondrial homeostasis and subsequent mitochondrial dysfunction play a key role in the pathophysiology of neurodegenerative diseases, further highlighting the importance of these organelles, especially in neurons. The maintenance of mitochondrial integrity through different surveillance mechanisms is thus critical for neuron survival. Mitochondria display a wide range of quality control mechanisms, from the molecular to the organellar level. Interestingly, many of these lines of defense have been found to be altered in neurodegenerative diseases such as PD and HD. Current knowledge and further elucidation of the novel pathways that protect the cell through mitochondrial quality control may offer unique opportunities for disease therapy in situations where ongoing mitochondrial damage occurs. In this review, we discuss the involvement of mitochondrial dysfunction in neurodegeneration with a special focus on the recent findings regarding mitochondrial quality control pathways, beyond the classical effects of increased production of reactive oxygen species (ROS) and bioenergetic alterations. We also discuss how disturbances in these processes underlie the pathophysiology of neurodegenerative disorders such as PD and HD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis

  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Laguna, Ariadna|||0000-0002-9732-6677
  • Romero-Giménez, Jordi|||0000-0002-8459-9895
  • Cuadros, Thais|||0000-0001-6994-2424
  • Bové, Jordi|||0000-0002-2529-205X
  • Martinez-Vicente, Marta|||0000-0001-7053-2625
  • Parent, Annabelle|||0000-0002-6195-812X
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Peñuelas, Núria|||0000-0001-6443-9790
  • Torra, Albert|||0000-0002-6852-7146
  • Rodríguez-Galván, Beatriz
  • Ballabio, Andrea|||0000-0003-1381-4604
  • Hasegawa, Takafumi
  • Bortolozzi, Analía|||0000-0002-2069-9192
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Vila Bover, Miquel|||0000-0002-1352-989X